Positions Merck to Capitalize on Opportunities for Global Growth
WHITEHOUSE STATION, N.J. — Merck Co., Inc. (NYSE: MRK), known outside the U.S. and Canada as MSD,
today provided further detail on integration plans for the companys
research and development, manufacturing and other business operations as
part of a global restructuring program announced following the November
2009 merger of Merck and Schering-Plough. The consolidation plans
support Mercks strategic direction as a customer focused, innovative
and diversified global health care company, and position the company to
invest in key areas for future growth, including emerging markets,
biologics, vaccines and consumer care.
Merck today announced plans to phase out operations at eight research
sites and eight manufacturing sites, as well as to continue to
consolidate office facilities worldwide, as part of the global merger
restructuring program that began last December. The goal of the
restructuring is to create a flexible RD organization that cultivates
scientific innovation, facilitates external collaboration and drives
pipeline progress and a reliable, more fully utilized and cost efficient
worldwide manufacturing supply chain to support Mercks broader product
portfolio.
Merck continues to expect its total workforce to be reduced by
approximately 15 percent across all areas of the combined company
worldwide as part of the initial phases of its merger restructuring
program. The company said it will continue to hire new employees in
strategic growth areas of the business as necessary.
“Today’s announcement is another important step as we successfully
integrate our global operations on schedule and move forward with
Mercks strategic priorities,” said Richard T. Clark, chairman and chief
executive officer of Merck. “These changes are crucial to drive future
growth and realize the promise of being a global health care leader for
the long term. While we believe these actions are necessary to support
Mercks competitive advantage, they required difficult decisions that
will impact some of our colleagues, their families and local
communities. We will implement our restructuring plans with the utmost
care and respect for the hard-working and talented employees of Merck,”
he said.
PORTLAND, Ore. — Bioject Medical Technologies Inc. (OTCBB: BJCT), a leading developer of
needle-free injection therapy systems, today announced that Bioject’s
needle-free injection delivery technology was used to successfully
demonstrate that intradermal administration of fractional doses of
inactivated poliovirus vaccine given to infants is safe and effective
(using seroconversion as an indication of effectiveness), and is
preferred by both health care administrators and parents over typical
full-dose needle and syringe. The study results, published in the June
24, 2010, issue of The New England Journal of Medicine (NEJM
Vol. 362 No. 25), also demonstrated a significant cost savings
in use of the fractional-dose intradermal injection as compared with a
full-dose vaccination course of treatment using an auto-disable needle
and syringe.
The study was conducted in Oman and supported by the Ministry of Health
of Oman, the Program for Appropriate Technology in Health (PATH) and the
World Health Organization (WHO) as part of the Global Polio Eradication
Initiative (GPEI). The randomized clinical trial of over 400 infants, of
whom 373 fulfilled the entry criteria, were selected to receive either
fractional-dose inactivated poliovirus vaccine (one-fifth of the full
dose) or a full-dose of the same vaccine over a three course treatment
during the first six months of age. The intradermal fractional-dose was
given with Bioject’s Biojector®2000 (B2000) needle-free injection
delivery device and the full-dose was delivered with an auto-disable
syringe and needle. The study was designed to assess the safety and
efficacy of, and preference for, the needle-free intradermal
fractional-dose and the potential to use a needle-free intradermal
fractional-dose vaccine option with infants in order to prevent polio
infection. The results of the study demonstrate that needle-free
intradermal administration of fractional doses of the polio vaccine was
safe, effective and lower cost than a similar course treatment with full
dose needle-syringe option. In addition, both health caregivers and
parents expressed a preference for the needle-free option because “the
baby does not cry.”
The study was one of the research and development initiatives stemming
from the GPEI’s goal to develop affordable injectable polio vaccine
options for the post-eradication era. GPEI is spearheaded by national
governments, WHO, Rotary International, the US Centers for Disease
Control and Prevention (CDC) and UNICEF.
“We are pleased to have participated in this significant clinical trial
and to learn about the positive results with intradermal fractional-dose
injection of inactivated polio vaccine using Bioject’s intradermal
delivery technology,” said Dr. Richard Stout, Bioject’s Executive Vice
President and Chief Medical Officer. Dr. Stout added, “Based on the
findings, as reported in the NEJM, we now have evidence that
demonstrates potential cost savings when using intradermal needle-free
injection delivery technology as compared with typical full-dose
injections. In addition, we along with the parents of the treated
infants are delighted to hear that the babies did not cry, leading to a
significant preference for Bioject’s needle-free injection devices. We
look forward to working with other organizations around the world who
are interested in leveraging the benefits of our needle-free intradermal
injection delivery technology for their vaccine portfolios,” commented
Dr. Stout.
Bioject Medical Technologies Inc., based in Portland, Oregon, is
an innovative developer and manufacturer of needle-free injection
therapy systems (NFITS). NFITS provide an empowering technology and work
by forcing medication at high speed through a tiny orifice held against
the skin. This creates a fine stream of high-pressure fluid penetrating
the skin and depositing medication in the tissue beneath. The Company is
focused on developing mutually beneficial agreements with leading
pharmaceutical, biotechnology and veterinary companies.
Funds Earmarked to “.Encourage Cutting Edge and Innovative
Biomedical Exploration”
RUTHERFORD, Calif. — The International Mental Health Research Organization (IMHRO) today
announced a collaboration with the Johnson Johnson Corporate Office of
Science and Technology (COSAT). Under the terms of this collaboration,
COSAT will provide a $250,000 grant towards the funding of IMHROs
Rising Star Awards. COSATs grant will be matched by IMHRO to establish
the COSAT-IMHRO Rising Star Awards Program, which, in 2010, will fund
two Rising Star Awards.
The objective of the COSAT-IMHRO Rising Star Awards Program is to
advance the understanding of underlying disease mechanisms in bipolar
disorder, schizophrenia and major depression with the great potential to
benefit patients and the healthcare system. The IMHRO Rising Star Awards
support cutting edge research programs throughout the world on the study
of psychiatric brain disorders, and are distributed annually at the
Staglin Family Music Festival For Mental Health, held this year in
September in Rutherford, Napa Valley, California.
“Our approach at IMHRO is to fund the best science as determined by our
independent scientific advisory board,” stated Garen Staglin, co-founder
of IMHRO, and proprietor of Staglin Family Vineyard. “This collaboration
will fund research of key scientists and will bring us closer than ever
to helping find the causes and cures for mental illness.”
The COSAT-IMHRO Rising Star Awards Program is intended to advance the
translation of discoveries from basic science research into therapies
for major psychiatric diseases. Understanding the mechanism of action
and the role in the brain of genes that are altered in psychiatric
disease supplies the first clue as to how these disorders arise. This
grant program fosters the next steps toward discovering therapies
through research into approaches that re-normalize or compensate for the
alterations that have already been discovered.
naturopath perth
|| tags: Uncategorized author: admin comments: No Comments